Publication Type Journal Article
Title Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine
Authors Shrika G. Harjivan Catarina Charneira Ines L. Martins Sofia A. Pereira Guadalupe Espadas Eduard Sabido Frederick A. Beland M. Matilde Marques Alexandra Maria Moita Antunes
Groups BIOMOL
Journal MOLECULES
Year 2021
Month March
Volume 26
Number 5
Pages
Abstract Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor widely used in combined antiretroviral therapy and to prevent mother-to-child transmission of the human immunodeficiency virus type 1, is associated with several adverse side effects. Using 12-mesyloxy-nevirapine, a model electrophile of the reactive metabolites derived from the NVP Phase I metabolite, 12-hydroxy-NVP, we demonstrate that the nucleophilic core and C-terminal residues of histones are targets for covalent adduct formation. We identified multiple NVP-modification sites at lysine (e.g., H2BK47, H4K32), histidine (e.g., H2BH110, H4H76), and serine (e.g., H2BS33) residues of the four histones using a mass spectrometry-based bottom-up proteomic analysis. In particular, H2BK47, H2BH110, H2AH83, and H4H76 were found to be potential hot spots for NVP incorporation. Notably, a remarkable selectivity to the imidazole ring of histidine was observed, with modification by NVP detected in three out of the 11 histidine residues of histones. This suggests that NVP-modified histidine residues of histones are prospective markers of the drug s bioactivation and/or toxicity. Importantly, NVP-derived modifications were identified at sites known to determine chromatin structure (e.g., H4H76) or that can undergo multiple types of post-translational modifications (e.g., H2BK47, H4H76). These results open new insights into the molecular mechanisms of drug-induced adverse reactions.
DOI http://dx.doi.org/10.3390/molecules26051349
ISBN
Publisher
Book Title
ISSN
EISSN 1420-3049
Conference Name
Bibtex ID ISI:000628433700001
Observations
Back to Publications List